Medication info
Dongkwang Pregabalin Capsule 50 mg

Dongkwang Pregabalin Capsule 50 mg

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›50mg / 1 capsule
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
Hard capsules with a blue upper part and white lower part containing a white powder
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201907774 · Approved 2019.11.06 · Insurance code 645906790

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a Initial dose (mg/day) | Maximum dose (mg/day) | Dosing regimen ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: Supplemental dose refers to a dose administered once in addition. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients 12-17 years of age: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the relief of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy, effective regardless of the presence of secondary general symptoms. Additionally, it helps treat symptoms of fibromyalgia. In summary, it is used for neuropathic pain, adjunctive therapy for partial seizures in epilepsy, and treatment of fibromyalgia.

How to take

Adult dose

This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a Initial dose (mg/day) | Maximum dose (mg/day) | Dosing regimen ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: Supplemental dose refers to a dose administered once in addition. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients 12-17 years of age: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behavior. Therefore, if there are changes in mood or abnormal behavior during treatment, consulting a physician immediately is essential. Patients with hypersensitivity to this medication or genetic issues like lactose intolerance should not take it. Diabetes patients should be cautious as weight gain may require adjustments in blood sugar control medications. If allergic reactions such as angioedema occur, the medication should be discontinued immediately, and medical personnel should be informed. The elderly should be particularly careful in the initial stages of treatment due to the risk of falling or injury from dizziness and drowsiness. If there are changes in vision or other persistent abnormalities, notify a physician. Stopping this medication abruptly may lead to withdrawal symptoms such as insomnia, headache, and anxiety; tapering off according to a physician's instructions is recommended. Patients with a history of substance abuse should use this medication cautiously due to the potential for misuse or dependence. Patients with reduced kidney function may require dosage adjustments. Caution is advised for patients with heart disease while taking this medication. When taken with opioid analgesics, there is a risk of central nervous system depression; caution is advised when combining these medications. Patients with respiratory or neurological conditions, or the elderly, are at higher risk of severe respiratory depression; they may require dosage adjustments. Pregnant women should not take this medication in early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. Breastfeeding may transmit this medication to breast milk and affect infants; consider discontinuing either breastfeeding or the medication. Before driving or operating hazardous machinery, ensure that the medication does not cause dizziness or drowsiness. Severe skin reactions may occur; discontinue immediately and consult with medical personnel if there are any skin abnormalities. In case of overdose, symptoms may include altered consciousness, drowsiness, and depression, and treatment such as dialysis may be required.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 213 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • respiratory failure
  • coma
  • death
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual arousal disorder
  • restlessness
  • anxiety
  • mood instability
  • emotional decline
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attack
  • lack of impulse control
  • apathy
  • ataxia
  • abnormal motor coordination
  • equilibrium disorder
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • orthostatic dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • stupor
  • bradykinesia
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • ocular edema
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • upon vibration
  • change in depth perception of vision
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • dry nasal passages
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • sialorrhea
  • gastroesophageal reflux disease
  • oral sensory reduction
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • voiding dysfunction
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast hypertrophy
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • drunkenness sensation
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • elevated alanine aminotransferase
  • increased serum creatine phosphokinase
  • elevated aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylactic-like symptoms
  • skin-mucous membrane syndrome
  • erythema multiforme
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • agitation
  • restlessness
  • worsening of seizures
  • blood in stool
  • gastrointestinal disturbances
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • fatigue
  • weakness
  • gait abnormalities
  • sleep disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly closed container. It is recommended to maintain a storage temperature between 15 to 30 degrees Celsius to safely preserve the medication's efficacy.

Appearance and packaging

Appearance

Hard capsules with a blue upper part and white lower part containing a white powder

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.